Irinotecan plus fluorouracil/folinic acid: increased risk of death?

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2001年 / 882卷 / 1期
关键词：
Fluorouracil; Irinotecan; Oxaliplatin; Leucovorin; Folinic Acid;
D O I：
10.2165/00128415-200108820-00010
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：6 / 6
相关论文
共 50 条
  • [1] Fluorouracil/folinic acid/irinotecanRheumatoid arthritis (first report with irinotecan): case report
    Reactions Weekly, 2006, 1087 (1) : 14 - 14
  • [2] Biweekly irinotecan plus bolus 5-fluorouracil and folinic acid in patients with advanced stage colorectal cancer
    Yalcin, S
    Oksuzoglu, B
    Tekuzman, G
    Engin, H
    Celik, I
    Turker, A
    Barista, I
    Gullu, I
    Guler, N
    Altundag, K
    Ozisik, Y
    Kars, A
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2003, 33 (11) : 580 - 583
  • [3] Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer
    Rehman, Sana Saif Ur
    Lim, Kian
    Wang-Gillam, Andrea
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (05) : 485 - 492
  • [4] Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer
    von Weikersthal, Ludwig Fischer
    Schalhorn, Andreas
    Stauch, Martina
    Quietzsch, Detlef
    Maubach, Peter A.
    Lambertz, Helmut
    Oruzio, Daniel
    Schlag, Rudolf
    Weigang-Koehler, Karin
    Vehling-Kaiser, Ute
    Schulze, Manfred
    Truckenbrodt, Juergen
    Goebeler, Mariele
    Mittermueller, Johann
    Bosse, Daniel
    Szukics, Borika
    Grundeis, Marc
    Zwingers, Thomas
    Giessen, Clemens
    Heinemann, Volker
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (02) : 206 - 214
  • [5] A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients
    Garufi, C
    Bria, E
    Vanni, B
    Zappalà, AMR
    Sperduti, I
    Terzoli, E
    BRITISH JOURNAL OF CANCER, 2003, 89 (10) : 1870 - 1875
  • [6] A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients
    C Garufi
    E Bria
    B Vanni
    A M R Zappalà
    I Sperduti
    E Terzoli
    British Journal of Cancer, 2003, 89 : 1870 - 1875
  • [7] Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group
    Comella, Pasquale
    Lorusso, Vito
    Maiorino, Luigi
    Casaretti, Rossana
    Cannone, Michele
    Massidda, Bruno
    Putzu, Carlo
    Leo, Silvana
    Roselli, Mario
    Mancarella, Sergio
    Palmeri, Sergio
    Greco, Ettore
    Vessia, Giacomo
    Sandomenico, Claudia
    Franco, Luca
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (05) : 893 - 899
  • [8] Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines
    J-L Fischel
    P Rostagno
    P Formento
    A Dubreuil
    M-C Etienne
    G Milano
    British Journal of Cancer, 2001, 84 : 579 - 585
  • [9] Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines
    Fischel, JL
    Rostagno, P
    Formento, P
    Dubreuil, A
    Etienne, MC
    Milano, G
    BRITISH JOURNAL OF CANCER, 2001, 84 (04) : 579 - 585
  • [10] Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial
    Dalla Chiesa, Matteo
    Tomasello, Gianluca
    Buti, Sebastiano
    Rovere, Rodrigo Kraft
    Brighenti, Matteo
    Lazzarelli, Silvia
    Donati, Gianvito
    Passalacqua, Rodolfo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (01) : 41 - 48
12345